ATE44765T1 - Lebend-impfstoff und verfahren zu dessen herstellung. - Google Patents

Lebend-impfstoff und verfahren zu dessen herstellung.

Info

Publication number
ATE44765T1
ATE44765T1 AT82305632T AT82305632T ATE44765T1 AT E44765 T1 ATE44765 T1 AT E44765T1 AT 82305632 T AT82305632 T AT 82305632T AT 82305632 T AT82305632 T AT 82305632T AT E44765 T1 ATE44765 T1 AT E44765T1
Authority
AT
Austria
Prior art keywords
gene
allergen
vertebrate
pathogen
production
Prior art date
Application number
AT82305632T
Other languages
English (en)
Inventor
Iii Roy Curtiss
Original Assignee
Research Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Research Corp filed Critical Research Corp
Application granted granted Critical
Publication of ATE44765T1 publication Critical patent/ATE44765T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/315—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A61K39/0275—Salmonella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A61K39/092—Streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1048—Glycosyltransferases (2.4)
    • C12N9/1051—Hexosyltransferases (2.4.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/542—Mucosal route oral/gastrointestinal
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AT82305632T 1981-10-22 1982-10-22 Lebend-impfstoff und verfahren zu dessen herstellung. ATE44765T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US31403081A 1981-10-22 1981-10-22
EP82305632A EP0080806B1 (de) 1981-10-22 1982-10-22 Lebend-Impfstoff und Verfahren zu dessen Herstellung

Publications (1)

Publication Number Publication Date
ATE44765T1 true ATE44765T1 (de) 1989-08-15

Family

ID=23218251

Family Applications (1)

Application Number Title Priority Date Filing Date
AT82305632T ATE44765T1 (de) 1981-10-22 1982-10-22 Lebend-impfstoff und verfahren zu dessen herstellung.

Country Status (7)

Country Link
EP (1) EP0080806B1 (de)
JP (2) JPH0811735B2 (de)
AT (1) ATE44765T1 (de)
CA (1) CA1338705C (de)
DE (1) DE3279824D1 (de)
GR (1) GR76769B (de)
IE (1) IE55478B1 (de)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4632830A (en) * 1981-07-31 1986-12-30 The United States Of America As Represented By The Secretary Of The Army Oral vaccine for immunization against enteric disease
CA1338705C (en) * 1981-10-22 1996-11-12 Roy Curtiss Iii Vaccines obtained from antigenic gene products of recombinant genes
US4888170A (en) * 1981-10-22 1989-12-19 Research Corporation Vaccines obtained from antigenic gene products of recombinant genes
GB8314645D0 (en) * 1983-05-26 1983-06-29 Wellcome Found Bivalent vaccines
US4784948A (en) * 1983-08-10 1988-11-15 The Rockefeller University Production of streptococcal m protein immunogens and molecular probes
AU589114B2 (en) * 1984-02-01 1989-10-05 Enterovax Limited Genetically engineered bacteria useful as a vaccine
US5288617A (en) * 1984-10-31 1994-02-22 Commonwealth Scientific And Industrial Research Organization Method of producing an antigenic preparation
CA1331355C (en) * 1986-04-21 1994-08-09 Bioenterprises Pty. Ltd Immunopotentation
EP0250614A1 (de) * 1986-06-23 1988-01-07 Serum Und Impfinstitut Und Institut Zur Erforschung Der Infektionskrankheiten Schweiz. Chromosomale Nukleotid-DNS-Fragmente, die für Zuckersynthetasen und Glukosyltransferasen kodieren
US5204097A (en) * 1986-07-06 1993-04-20 Yeda Research And Development Company Limited Shiga toxin B chain polypeptides and vaccine thereto
US5976839A (en) * 1987-03-13 1999-11-02 Bioenterprises Pty Limited Immunopotentiation through covalent linkage between immunogen and immunopotentiating molecules
IL86583A0 (en) * 1987-06-04 1988-11-15 Molecular Eng Ass Vaccine containing a derivative of a microbe and method for the production thereof
JPH04501351A (ja) * 1987-10-07 1992-03-12 ワシントン ユニバーシティ 細胞の遺伝的集団において所望の組換え遺伝子を維持する方法
IL91525A0 (en) * 1988-09-06 1990-04-29 Univ Washington Transgenic plants,pharmaceutical compositions containing the same and methods for the preparation thereof
DE69027112T2 (de) * 1989-01-23 1997-01-09 Auspharm International Ltd 4Th Impfstoffzusammensetzung
US5149532A (en) * 1989-11-01 1992-09-22 Cedars Sinai Medical Center Method of vaccine or toxoid preparation and immunization by colonization with recombinant microorganisms
ATE234917T1 (de) * 1990-11-09 2003-04-15 Univ Washington Avirulente salmonella mikroben mit einer mutation in dem cdt gen und ihre verwendung
US6511845B1 (en) 1992-08-07 2003-01-28 Alan R. Davis Methods for producing an immune response against HIV-1
CA2154379A1 (en) * 1994-07-22 1996-01-23 Shyam S. Mohapatra Parietaria allergens
DK0775746T3 (da) 1995-07-03 2006-04-03 Akzo Nobel Nv Vaccine mod fjerkræcoccidiose
US6221364B1 (en) 1996-11-12 2001-04-24 Albert Einstein College Of Medicine Of Yeshiva University Recombinant mycobacteria auxotrophic for diaminopimelate
US7879977B2 (en) 1998-01-31 2011-02-01 University Of Arkansas Methods and reagents for decreasing clinical reaction to allergy
EP1057892A1 (de) * 1999-06-02 2000-12-06 Centrum voor Onderzoek in Diergeneeskunde en Agrochemie Attenuierte mutante enteropathogenische E.coli-Stämme (EPEC), deren Herstellungsverfahren und Verwendungen
EP1272213B1 (de) 2000-04-06 2006-03-08 SEER Pharmaceuticals, LLC. Microbielles wirkstoffabgabesystem
US8246945B2 (en) 2000-04-06 2012-08-21 University Of Arkansas Methods and reagents for decreasing clinical reaction to allergy
ATE489946T1 (de) * 2000-05-26 2010-12-15 Kanji Takada Nicht-orale zubereitung mit einer dreischicht- struktur

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1472624A (en) * 1974-09-02 1977-05-04 Canadian Patents Dev Enteric disease vaccine
US4237224A (en) * 1974-11-04 1980-12-02 Board Of Trustees Of The Leland Stanford Jr. University Process for producing biologically functional molecular chimeras
DE2530275A1 (de) * 1975-07-07 1977-01-27 Max Planck Gesellschaft Salmonella-coli-hybride, verfahren zu deren herstellung und vermehrung und apathogener lebend-impfstoff gegen salmonellosen
NO158880C (no) * 1977-11-08 1988-11-09 Genentech Inc Fremgangsmaate for fremstilling av et spesifikt pattedyrhormon.
US4133875A (en) * 1978-02-23 1979-01-09 Forsyth Dental Infirmary For Children Method of controlling dental caries with streptococcus mutans mutant strains
GB2033223B (en) * 1978-09-01 1983-09-14 Secr Social Service Brit Antigen fromstreptococcus mutans for protection against dental caries
FR2442271A1 (fr) * 1978-11-27 1980-06-20 Pasteur Institut Vecteur permettant l'insertion d'un gene procaryote ou eucaryote, et l'excretion de la proteine exprimee
DE2942780A1 (de) * 1979-10-23 1981-05-21 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V., 3400 Göttingen Eukaryotische zellen, eukaryotische protoplasten und vielzellige eukaryotische lebende organismen mit einem gehalt an durch lipidvesikel eingebrachter dna, verfahren zu ihrer herstellung von gen-produkten, zur immunisierung und zur behebung genetisch bedingter defekte
US4250262A (en) * 1979-12-14 1981-02-10 Forsyth Dental Infirmary For Children Method of preparing a purified glucosyltransferase
FR2490239A1 (fr) * 1980-09-18 1982-03-19 Wellcome Found Molecule d'acide desoxyribonucleique comprenant une sequence de nucleotides correspondant a des proteines du virus de la fievre aphteuse, son procede d'obtention et vaccin obtenu
AU559550B2 (en) * 1981-03-09 1987-03-12 Cetus Corporation Vaccines
GB2103622B (en) * 1981-06-16 1986-01-15 Genentech Inc Production of foot and mouth disease vaccine from microbially expressed antigens
EP0068719A3 (de) * 1981-06-16 1984-03-28 Takeda Chemical Industries, Ltd. Desoxyribonukleine Säuren, deren Herstellung und Verwendung
CA1338705C (en) * 1981-10-22 1996-11-12 Roy Curtiss Iii Vaccines obtained from antigenic gene products of recombinant genes

Also Published As

Publication number Publication date
DE3279824D1 (en) 1989-08-24
CA1338705C (en) 1996-11-12
EP0080806B1 (de) 1989-07-19
GR76769B (de) 1984-09-03
JPH06165688A (ja) 1994-06-14
IE55478B1 (en) 1990-09-26
EP0080806A1 (de) 1983-06-08
JPS58126815A (ja) 1983-07-28
IE822543L (en) 1983-04-22
JP2777622B2 (ja) 1998-07-23
JPH0811735B2 (ja) 1996-02-07

Similar Documents

Publication Publication Date Title
DE3279824D1 (en) Live vaccine and its method of production
ATE61228T1 (de) Immunogener protein- oder peptidkomplex, verfahren zur herstellung dieses komplexes und seine verwendung als immunstimulans und als impfstoff.
DE69431404D1 (de) Verfahren zur mikroverkapselung von antigenen und verwendung der zusammensetzungen als impfstoffe
ES8203226A1 (es) Procedimiento de preparar complejos vacunantes por reaccion de arn ribonosales y de antigenos especificos.
ATE295895T1 (de) Genetischer impfstoff gegen den immunschwäche virus
DK0524205T3 (da) Levende vacciner
DK153290D0 (da) Polypeptid, vaccine indeholdende dette og ekspressionssystem indeholdende en dna-sekvens, der kan udtrykke polypeptidet
ES548397A0 (es) Un metodo para producir normas orales frente a virus de hepatitis-b.
BR8807376A (pt) Microorganismo atenuado,composicao farmaceutica e processo de produzir um microorganismo atenuado
DE3575520D1 (de) Rabies-vakzine und verfahren zur herstellung.
DE69132417D1 (de) Impfstoff gegen die Lyme-Krankheit
NZ502144A (en) Multi-subtype FIV vaccines
ATE162550T1 (de) Ospc-antigen-impfstoffe immunogene zusammensetzung zur vorbeugung und behandlung von lyme-krankheit und rekombinante verfahren zur herstellung von derartige antigene
ATE149569T1 (de) Verfahren zur herstellung von impfstoffen oder toxoiden
IE940698L (en) Vaccine and serum for endotoxin associated disease and method of preparing same as well as to methods of immunization and treatment of such disease and to a detoxified endotoxin and bacterial mutant
ATE73349T1 (de) Hepatitisoberflaechenantigenpartikelvakzin.
ATE102650T1 (de) Mutanten des infektioesen bovinen rhinotracheitisvirus, vakzine die sie enthalten, verfahren zu ihrer herstellung und ihrer verwendung.
DE69534635D1 (de) Verfahren zur produktion von verstärkt antigen wirkenden heliobacter sp. und vakzine die diesen enthalten
EP0636030A4 (de) Impfstoff gegen das bacterientoxoid aus -i (pasteurellia haemolytica).
NO307815B1 (no) Levende eller inaktivert parental vaksine mot rotavirusinfeksjon
GB9404577D0 (en) Vaccine compositions
GB8431253D0 (en) Biological preparations
GR3020495T3 (en) Two-phase system for the production and presentation of foreign antigens in hybrid live vaccines
Mohamed STUDIES OF IMMUNITY TO PASTEURELLA MULTOCIDA (PASTEURELLOSIS, RESPIRATORY DISEASES)
Wiblin , JL Melnick (Ed.) Progress in Medical Microbiology, Vol. 31, S. Karger (1985)

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
EEIH Change in the person of patent owner
EELA Cancelled due to lapse of time